Diabetic retinopathy (DR) is the leading cause of blindness in working-age adults in the US. Proliferative DR (PDR) is an advanced stage of DR associated with the growth of abnormal retinal blood vessels, often referred to as neovascularization (NV). These neovessels can lead to hemorrhaging, vitreous scarring and retinal detachment, often resulting in irreversible vision loss. Numerous studies have shown that vascular endothelial growth factor (VEGF) plays an important role in the development of retinal NV associated with PDR. Laser treatment and/or anti-VEGF therapies are often used to control PDR; unfortunately, both have their drawbacks. Laser treatment is not curative and can damage healthy tissues. Anti-VEGF therapies, administered by intravitreal injection, carry the risk of endophthalmitis and are not efficacious in a significant fraction of diabetics. Methods allowing the informed modification of therapeutic regimes over the course of PDR are needed to improve patient outcomes. To develop such methods, retinal mRNAs associated with NV must be evaluated as predictive biomarkers and then exploited as a basis for retinal imaging. Retinal mRNA biomarkers offer the potential to image the onset, development and resolution of retinal NV in relation to therapeutic response. Interestingly, increased levels of endoglin mRNA occur in PDR. In experimental proliferative retinopathy, endoglin mRNA is detected at loci of incipient NV lesions and remains localized to these developing structures. Furthermore, anti-endoglin antibodies block experimental retinal NV. Taken together, these studies indicate that endoglin mRNA is intrinsically linked to NV development and progression suggesting that it is well-suited as a molecular target for imaging retinal NV. This proposal outlines a research plan to investigate the application of a novel strategy for transfection-free targeted delivery of short hairpin-RNA-lipid conjugates, incorporating an anti- sense sequence complimentary to endoglin (AS-ENG-shRNA-lipid). These AS-ENG-shRNA-lipid conjugates are rapidly internalized by cells and tissues, and they incorporate a dye that becomes fluorescently active upon hybridization to endoglin mRNA allowing their use as optical imaging probes. In this proposal, we describe experiments designed to test the capacity of AS-ENG-shRNA-lipid conjugates to image endoglin mRNA in retinal microvascular endothelial cells (RMEC) cultured under DR-relevant conditions. The mechanism(s) of AS-ENG- shRNA-lipid uptake by RMEC will also be determined. In vivo retinal imaging experiments will be performed in a mouse model of oxygen-induced retinopathy (OIR). OIR mice demonstrate a robust retinal neovascular response that is responsive to anti-VEGF therapy. We will test the capacity of AS-ENG-shRNA-lipid conjugates to longitudinally image retinal NV over the course of mouse OIR and in response to anti-VEGF therapy. Lastly, we will assess the in vivo biodistribution, pharmacokinetic, and toxicity of AS-ENG-shRNA-lipid conjugates in mice. This research will facilitate the clinical translation of this new imaging methodology for improved management of diabetic retinopathy and other ocular neovascular conditions. !

Public Health Relevance

Neovascularization (NV) is a common complication of blinding retinal diseases like diabetic retinopathy, age- related macular degeneration and retinopathy of prematurity. Endoglin (CD105), a transmembrane auxiliary receptor for transforming growth factor-beta (TGF-?), exhibits increased expression in proliferating endothelial cells at the earliest stages of retinal NV development. In this proposed study, a novel mRNA imaging method developed by the applicants will be tested in vivo as a diagnostic tool to predict the onset of NV, track NV progression and evaluate NV response to therapy.

Agency
National Institute of Health (NIH)
Institute
National Eye Institute (NEI)
Type
Research Project (R01)
Project #
5R01EY023397-08
Application #
9930636
Study Section
Diseases and Pathophysiology of the Visual System Study Section (DPVS)
Program Officer
Greenwell, Thomas
Project Start
2013-03-01
Project End
2023-05-31
Budget Start
2020-06-01
Budget End
2021-05-31
Support Year
8
Fiscal Year
2020
Total Cost
Indirect Cost
Name
Vanderbilt University Medical Center
Department
Type
DUNS #
079917897
City
Nashville
State
TN
Country
United States
Zip Code
37232
Uddin, Md Imam; Jayagopal, Ashwath; Wong, Alexis et al. (2018) Real-time imaging of VCAM-1 mRNA in TNF-? activated retinal microvascular endothelial cells using antisense hairpin-DNA functionalized gold nanoparticles. Nanomedicine 14:63-71
Jackson, S R; Wong, A C; Travis, A R et al. (2016) Applications of Hairpin DNA-Functionalized Gold Nanoparticles for Imaging mRNA in Living Cells. Methods Enzymol 572:87-103
Uddin, Md Imam; Evans, Stephanie M; Craft, Jason R et al. (2016) In Vivo Imaging of Retinal Hypoxia in a Model of Oxygen-Induced Retinopathy. Sci Rep 6:31011
Uddin, Md Jashim; Moore, Chauca E; Crews, Brenda C et al. (2016) Fluorocoxib A enables targeted detection of cyclooxygenase-2 in laser-induced choroidal neovascularization. J Biomed Opt 21:90503
Jia, Yali; Liu, Gangjun; Gordon, Andrew Y et al. (2015) Spectral fractionation detection of gold nanorod contrast agents using optical coherence tomography. Opt Express 23:4212-25
Gahlaut, Nivriti; Suarez, Sandra; Uddin, Md Imam et al. (2015) Nanoengineering of therapeutics for retinal vascular disease. Eur J Pharm Biopharm 95:323-30
Evans, Stephanie M; Kim, Kwangho; Moore, Chauca E et al. (2014) Molecular probes for imaging of hypoxia in the retina. Bioconjug Chem 25:2030-7
May, James M; Jayagopal, Ashwath; Qu, Zhi-Chao et al. (2014) Ascorbic acid prevents high glucose-induced apoptosis in human brain pericytes. Biochem Biophys Res Commun 452:112-7
Gordon, Andrew Y; Jayagopal, Ashwath (2014) Engineering of Nanoscale Contrast Agents for Optical Coherence Tomography. J Nanomed Nanotechnol Suppl 5:004
Zhou, Qinbo; Anderson, Chastain; Zhang, Hongmei et al. (2014) Repression of choroidal neovascularization through actin cytoskeleton pathways by microRNA-24. Mol Ther 22:378-389